4.5 Article

Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)

期刊

ACS MEDICINAL CHEMISTRY LETTERS
卷 13, 期 1, 页码 84-91

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.1c00473

关键词

HPK1; immuno-oncology; structure-based design; kinase inhibitor; CYP inhibition

向作者/读者索取更多资源

HPK1, identified as a negative regulator of T-cell activation, has potential implications in tumor therapy. Through structure-based drug design, a series of small molecule inhibitors of HPK1 were discovered with significantly improved kinase selectivity, showing potential therapeutic value in tumor treatment.
Hematopoietic progenitor kinase 1 (HPK1) is implicated as a negative regulator of T-cell receptor-induced T-cell activation. Studies using HPK1 kinase-dead knock-in animals have demonstrated the loss of HPK1 kinase activity resulted in an increase in T-cell function and tumor growth inhibition in glioma models. Herein, we describe the discovery of a series of small molecule inhibitors of HPK1. Using a structure-based drug design approach, the kinase selectivity of the molecules was significantly improved by inducing and stabilizing an unusual P-loop folded binding mode. The metabolic liabilities of the initial 7-azaindole high-throughput screening hit were mitigated by addressing a key metabolic soft spot along with physicochemical property-based optimization. The resulting spiro-azaindoline HPK1 inhibitors demonstrated improved in vitro AD ME properties and the ability to induce cytokine production in primary human T-cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据